Skip to main content

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Prelude Therapeutics Inc changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of PRLD: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders5047−3
Shares27.2M27.2M−26.0K (−0.1%)
Value$22.0M$39.1M+$17.1M (+77.8%)

New holders (5)

Institutions that held Prelude Therapeutics Inc at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to PRLD in Q3 2025
InstitutionSharesValue% of portfolio
Prudential Financial Inc25,840$37.2K0.00%
HRT Financial LP16,901$24.0K0.00%
Optiver Holding B.V.20$290.00%
SRS Capital Advisors, Inc.15$220.00%
Simplex Trading, LLC153$00.00%

Sold out (8)

Institutions that held Prelude Therapeutics Inc at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of PRLD in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Cantor Fitzgerald, L. P.211,859$171.5K
Charles Schwab Investment Management Inc80,845$65.4K
Y-Intercept (Hong Kong) Ltd47,788$38.7K
Marshall Wace, LLP41,747$33.8K
Susquehanna International Group, LLP39,977$32.4K
Citadel Advisors LLC33,625$27.2K
Wells Fargo & Company297$240
True Wealth Design, LLC13$11